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A B S T R A C T
The breath-actuated mechanism (BAM) is a mechanical unit included in NEXThaler® with the role of delaying the
emission of the drug until the inhalation ﬂow rate of the patient is suﬃciently high to detach the drug particles
from their carriers.
The main objective of this work was to analyse the eﬀect of the presence of BAM on the size distribution of the
emitted drug and its airway deposition eﬃciency and distribution. Study of the hygroscopic growth of the
emitted drug particles and its eﬀect on the deposition was another goal of this study.
Size distributions of Foster® NEXThaler® drug particles emitted by dry powder inhalers with and without BAM
have been measured by a Next Generation Impactor. Three characteristic inhalation proﬁles of asthmatic pa-
tients (low, moderate and high ﬂow rates) were used for both experimental and modelling purposes. Particle
hygroscopic growth was determined by a new method, where experimental measurements are combined with
simulations. Upper airway and lung deposition fractions were computed assuming 5 s and 10 s breath-hold
times.
By the inclusion of BAM the ﬁne particle fraction of the steroid component increased from 24 to 30% to
47–51%, while that of bronchodilator from 25–34% to 52–55%. The predicted upper airway steroid and
bronchodilator doses decreased from about 60% to 35–40% due to BAM. At the same time, predicted lung doses
increased from about 20%–35% (steroid) and from 22% to 38% (bronchodilator) for the moderate ﬂow proﬁle
and from about 25% to 40% (steroid) and from 29% to 47% (bronchodilator) for the high inhalation ﬂow proﬁle.
Although BDP and FF upper airway doses decreased by a factor of about two when BAM was present, lung doses
of both components were about the same in the BAM and no-BAM conﬁgurations at the weakest ﬂow proﬁle.
However, lung dose increased by 2–3% even for this proﬁle when hygroscopic growth was taken into account.
In conclusion, the NEXThaler® BAM mechanism is a unique feature enabling high emitted ﬁne particle
fraction and enhanced drug delivery to the lungs.
1. Introduction
Foster® NEXThaler® is an ICS + LABA (inhaled corticosteroid and
long-acting β2-agonist) ﬁxed combination aerosol drug used in current
COPD and asthma therapy (Crisafulli et al., 2016). According to the SPC
(summary of product characteristics) of Foster® NEXThaler® each
metered dose of 10 mg powder contains 100 micrograms of beclome-
tasone dipropionate anhydrous (BDP) and 6 micrograms of formoterol
fumarate dihydrate (FF). As excipients, Foster® NEXThaler® contains
lactose monohydrate (about 9.9 mg, which contains small amounts of
milk protein), and magnesium stearate.
Based on the experimental measurements of several investigators
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(e.g. De Boer et al., 2015) the NEXThaler® inhaler is a DPI (dry powder
inhaler) device delivering an almost pressure-drop independent dose of
BDP and FF. It has also been demonstrated that Foster® NEXThaler®
emits a high fraction of ﬁne (diameter< 5 μm) and extraﬁne (dia-
meter< 2 μm) particles (Buttini et al., 2016) with high lung deposition
eﬃciency and a more uniform deposition distribution (Mariotti et al.,
2011). The special internal design and structure of the inhaler is con-
sidered to contribute to the above characteristics of the drug (Scichilone
et al., 2013). The most innovative feature of the device is the built in
BAM (breath-actuated mechanism). The BAM is a mechanical unit in-
tegrated into the NEXThaler® with the aim of delaying the emission of
the drug until the ﬂow rate of the patient is suﬃciently high (about
35 L/min). This level ﬂow rate causes high turbulence intensity inside
the cyclone chamber, resulting in eﬃcient detachment of drug particles
from the carriers. The detachment is promoted also by the strong col-
lisions between the particles with high kinetic energy and between the
particles and the walls of the device (Corradi et al., 2014). While
qualitatively the above reasoning seems to be logical and correct, a
systematic quantitative analysis of the eﬀect of the inclusion of BAM is
still missing in the literature. A number of investigators have analysed
by both Andersen Cascade Impactor (ACI) and Next Generation Im-
pactor (NGI) the size distribution of drug particles emitted by NEX-
Thaler® and proved that ﬁne and extraﬁne particle fractions (FPF and
EPF, that is, fractions of particles with aerodynamic diameter smaller
than 5 μm and 2 μm, respectively, expressed as per cents of metered
dose/label claim) are indeed high compared to the corresponding va-
lues of other DPI drugs in the market. Based on Table 1, which is a
summary of the measurement results gathered from the open literature,
the FPF is between 42.5% and 59.4% for BDP and between 43.3% and
56.7% for FF while the EPF is between 32% and 52.7% for BDP and
between 22.5% and 48.9% for FF, depending on the ﬂow rate of the
impactor. The corresponding mass median aerodynamic diameter
(MMAD) values were systematically low (between 1.1 μm and 1.7 μm).
However, it has not been analysed so far to what extent the ad-
vantageous aerodynamic characteristics of the emitted particles are due
to the BAM. By the same token, the high number of the resulting ﬁne
and extraﬁne drug particles should lead to lower deposited upper
airway doses and higher lung doses. To the best of our knowledge, an
analysis on the eﬀect of the presence of BAM on the amount of drug
deposited in diﬀerent regions of the airways is also missing. One way of
studying the eﬀect of BAM is to compute and compare the airway de-
position distributions of the drugs emitted by the inhalers with BAM
included and lacking it. Carefully validated numerical models proved to
be a powerful tool in the quantiﬁcation of total respiratory tract, re-
gional and local deposition distributions of diﬀerent drugs (e.g. Jókay
et al., 2016; Horváth et al.,2017). However, most of the numerical
models do not consider the growth of the inhaled particles due to the
humid environment within the airways. Aerodynamic properties of the
emitted aerosol drugs, like the parameters in Table 1, are also de-
termined under certain humidity and temperature conditions. Knowl-
edge of growth dynamics may be important also in the perspective of
drug development. If drug particles are suﬃciently small to enter the
lungs and their hygroscopic growth is signiﬁcant within particle re-
sidence time, then chances of exhalation decrease and lung deposition
will be higher.
The main objective of this study is to apply experimental techniques
to analyse the eﬀect of the inclusion of BAM on the main aerodynamic
characteristics of the emitted particles. Another aim is to use the
measured values as inputs of numerical models to characterize the
deposition distribution of the drugs in diﬀerent anatomical regions of
the airways and analyse the eﬀect of BAM on the deposition of Foster®
NEXThaler® drug. Finally, this study proposes to measure the hygro-
scopic growth of the drug particles emitted by NEXThaler® and to
analyse the possible eﬀect of their hygroscopic behaviour on the de-
posited drug dose distributions within the airways.
2. Methods
In this study both experimental techniques and numerical modelling
tools were applied. Experimental measurements were performed to
analyse the eﬀect of BAM on the aerodynamic properties of the emitted
particles. The results of these measurements were then used as inputs of
the numerical airway deposition model. Extended hygroscopicity
measurements of ICS and LABA drug components were also completed.
Realistic breathing proﬁles of asthmatic patients through the
NEXThaler® were used for both measurement and modelling purposes.
The original inhalation proﬁles were acquired by Scuri et al. (2013) on
41 asthmatic patients with varying levels of disease control while they
inhaled through the inhaler by using acoustic monitoring equipment.
Casaro et al. (2014) then processed these proﬁles and calculated the
p10, p50 and p90 representative proﬁles, which were adopted in our
study. The p10, p50 and p90 curves were generated by calculating the
10th, 50th and 90th percentile cohort values at each recorded time
interval (0.01 s). The p10, p50 and p90 inhalation proﬁles are char-
acterised by 1.0 s, 1.9 s and 3.4 s inhalation times, and 45 L/min, 60 L/
min and 100 L/min peak inspiratory ﬂow (PIF) values, respectively.
The three inhalation ﬂow curves are plotted in Fig. 1.
We now present the experimental and numerical techniques used in
this study.
2.1. Experimental method for the characterization of the emitted particles
The aim of experimental work was to measure and compare the
particle characteristics emitted by NEXThaler® DPI inhalers with and
Table 1
Summary of the measured ﬁne (< 5 μm) and extraﬁne (< 2 μm) particle fractions of the two drug components of Foster® NEXThaler® with diﬀerent impactors at diﬀerent ﬂow rates
retrieved in the open literature. FPF − ﬁne particle fraction; EPF − extraﬁne particle fraction.
Impactor type Flow rate (L/min) FPF (% of label claim) EPF (% of label claim) Author
BDP FF BDP FF
ACI 60 49.9 52.2 32.0 34.5 Zanker et al. (2011)
NGI 41.7 42.5 48.8 – – De Boer et al. (2015)
NGI 59 45.5 50.3 – – De Boer et al. (2015)
NGI 72.3 47.3 53.1 – – De Boer et al. (2015)
NGI 30 48.2 43.3 34.5 22.5 Buttini et al. (2016)
NGI 40 49.2 48.3 34.7 25.3 Buttini et al. (2016)
NGI 60 58.4 56.7 41.3 28.4 Buttini et al. (2016)
ACI 60 59.4 52.5 52.7 48.9 Buttini et al. (2016)
NGI 90 57.9 56.7 43.4 34.9 Buttini et al. (2016)
NGI realistic proﬁle, p10 45.9 45.3 36.4 30.8 Casaro et al. (2014)
NGI realistic proﬁle, p50 48.8 48.3 38.9 32.7 Casaro et al. (2014)
NGI realistic proﬁle, p90 47.4 44.5 36.8 28.8 Casaro et al. (2014)
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without BAM, and to provide realistic inputs for the airway deposition
model.
The inhalation proﬁles in Fig. 1 were implemented into the Copley
BRS 3000 Breath Simulator Model to apply realistic characteristic
breathing proﬁles in the in vitro aerosol performance analysis experi-
ments. This breathing simulator was part of our experimental setup also
containing an NGI demonstrated in Fig. 2.
A NEXThaler® (Lot 1043523 Exp 04/2019) was opened from its foil
pouch and rested for a minimum of 96 h at 25 °C and 70% RH before
testing to allow any antistatic charge to dissipate. Prior to any analysis,
ﬁve waste shots were actuated from the devices into a waste dosing unit
sampling apparatus (DUSA) set at 60 L/min. The use of ﬁve shots was
considered appropriate to ensure the necessary response of the detector
that was used to analyse the formoterol fumarate (the component with
the lowest mass) within the test samples. The device was weighted
(readability 0.01 mg) before and after each shot to ensure dose eva-
cuation. The NEXThaler® device was analysed using all three inhalation
proﬁles in Fig. 1. In order to characterize the aerosol cloud in the NGI a
steady state volumetric ﬂow rate was set at values relative to the peak
values reached in the various inhalation proﬁles (45 L/min for p10,
60 L/min for p50 and 100 L/min for p90). This is possible due to the
incorporation of the Copley ’ﬂow splitter’ into the system, located in-
between the Pre-separator and Throat. When the system is ’balanced’
the Copley BRS 3000 is used to generate the inhalation proﬁle that is
drawn in through in the inhaler and throat assembly. All NGI mea-
surements were conducted in triplicate and each test replicate was
based on ﬁve separate doses being delivered from each NEXThaler®
device. Additionally, the assessments were performed in a non-con-
secutive order. The NEXThaler® device was weighed before and after
each actuation to estimate the shot weight (mg). Samples were col-
lected from the throat, pre-separator and the NGI stages, and analysed
for BDF/FF content. A suitable solvent mixture of acetonitrile (ACN):
buﬀer (45:55) was used to collect and dissolve the samples. Test sam-
ples were analysed by Acquity Ultra Performance Liquid Chromato-
graphy (UPLC) with Photodiode Array Detector (PAD, Waters, Wilm-
slow UK), ACE Excel C18 Amide 100 × 2.1, 2 μm Column (Hichrom,
UK), with an injection volume of 10 μL and a ﬂow rate of 0.75 mL/min.
External standard solutions for formoterol fumarate (0.04 μg/ml sen-
sitivity check, 4 μg ml/1 calibration standard and 4 μg ml/1 veriﬁcation
standard), gradient method with a run time of 8 mins (Line A: 90:10
buﬀer: acetonitrile and Line B: 10:90 buﬀer: acetonitrile). The gradient
use was Line A = 100% at 0 min, 66% at 4 min, 25% at 7 min and
100% at 7.1 min. The UPLC procedure was veriﬁed for speciﬁcity,
linearity, reproducibility and system suitability. The device retention
could not be measured for the NEXThaler®, however it was possible to
measure the change in mass. In order to test the device without a BAM a
thin spatula was used to trigger the BAM before ﬁring the device. This
was achieved by inserting the spatula through the air inlet vents located
on top of the NEXThaler® and pushing downwards on the BAM ﬂap to
release the spring, opening the dose protector.
2.2. Measuring the hygroscopic growth dynamics of pharmaceutical aerosol
The relationship between the diameter of an aerosol droplet and the
relative humidity (RH) is important to accurately parameterize in any
lung inhalation model; the dynamic behaviour of the aerosol size
during inhalation can be expected to have a signiﬁcant eﬀect on where
the dose is delivered (Haddrell et al., 2014). Here, we report the hy-
groscopic properties of various pharmaceutical aerosols measured using
a single particle analysis technique termed the comparative kinetic
electrodynamic balance (CK-EDB). A detailed explanation of this tech-
nology has been reported previously (Rovelli et al., 2016; Davies et al.,
2013), and only a brief description will be given here (Fig. 3).
The reservoirs of two droplet-on-demand dispensers were ﬁlled and
positioned such that droplets could be injected directly into the trap,
one with a starting solution containing the pharmaceutical at a known
concentration and the other with pure water (Fig. 3, left). As a droplet is
dispensed, a slight charge ( < 5 fC) is imparted by the placement of an
induction electrode held at a ﬁxed DC bias close to the dispenser; the
presence of this charge enables the droplet to be strongly trapped by the
electrodynamic ﬁelds of the trap. Once trapped, the radius of the dro-
plet is probed by measuring the angularly dependent light scattering
(the phase function) from an incident laser at 532 nm. The phase
function is compared with simulations from Mie scattering theory to
infer the droplet radius. During the drying process of all the pharma-
ceuticals, the particles did not reach a water activity low enough to
form an amorphous solid as evidenced by the coherence of the phase
function. The phase function is measured at a frequency of 100 Hz until
the droplet reaches an equilibrium with the RH of the airﬂow,
achieving a steady aqueous liquid droplet size. Through sequentially
trapping droplets originating from the two dispensers, accurate esti-
mations of the water activity of the airﬂow that the pharmaceutical
containing droplet evaporates into can be inferred by the mass ﬂux
from the water droplet (Davies et al., 2013).
At any moment in time during the droplet evaporation, the mass
ﬂux of water from the droplet is dependent on the instantaneous water
activity which is dependent on the solution composition; this re-
lationship has been reported by Kulmala et al. (1993), and is used to
convert CK-EDB measurements to hygroscopic growth curves (Rovelli
et al., 2016). The relationship between mass ﬂux and water activity is
shown in Eq. (1):
Fig. 1. In vivo 10th, 50th and 90th percentile inhalation curves (p10, p50 and p90 pro-
ﬁles) of asthmatic patients adopted from Casaro et al. (2014).
Fig. 2. Experimental setup including the NGI impactor and BRS 3000 breathing simu-
lator.
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where I is the mass ﬂux of evaporating water and a is droplet radius. Sa
is the fractional saturation vapour pressure (equivalent to the water
activity in the droplet) at the speciﬁc composition of the droplet at each
moment in time. S∞ is the water activity of the airﬂow (as measured by
the probe water droplet), T∞ is the gas phase temperature, M is the
molecular mass of water, L is latent heat of evaporation, the transitional
correction factors are βM and βT for mass and heat transfer, D is vapour
diﬀusion coeﬃcient, pe(T∞) is pressure, K is the thermal conductivity of
the gas phase, and A is Stefan ﬂow correction.
Thus for an evaporating droplet (Fig. 3B), at each point in time the
mass ﬂux from the droplet can be used to calculate the fractional sa-
turation vapour pressure Sa (the water activity); every other quantity in
equation 1 is known, measurable or can be calculated. Since the starting
concentration and radius of the droplet is known, a dry radius of the
droplet can be calculated. From the ratio of the absolute radius of the
droplet at each moment in time to the dry radius, the radial growth
factor is readily calculated, providing a size-independent method for
representing the level of hygroscopic growth for the aerosol. This ap-
proach was used in this publication to determine the hygroscopic
growth of NaCl and lactose (the carrier in Foster® NEXThaler®).
For highly insoluble species (such as BDP and FF) a slightly diﬀerent
approach was taken. Insuﬃcient solute could be dissolved in water
alone to yield an evaporation curve with changing mass ﬂux similar in
Fig. 3. (A) Experimental setup of the CK-EDB. (B) From the dynamic behaviour of an aqueous lactose solution droplet injected into an airﬂow with an RH of 83%, the water activity of the
droplet at each moment in time can be calculated from the mass ﬂux from the droplet.
Fig. 4. (A) The radial growth factor of various organic species as a function of κ. (B) The
dynamic behaviour of a single droplet injected into an airﬂow with an RH of 92% where
the starting solution is an organic with a given κ value whose concentration is 13 g/L.
Table 2
Times elapsed from the beginning of inspiration until the aerosol bolus starts, reaches its
maximum and ends at p10, p50 and p90 ﬂow proﬁles in case of devices including a BAM
and without it.
Device Inh. proﬁle Start (s) Peak (s) End (s) Duration (ms)
NEXThaler® with
BAM
p10 0.44 0.49 0.60 164
p50 0.35 0.40 0.52 170
p90 0.30 0.35 0.48 180
NEXThaler® without
BAM
p10 0.18 0.26 0.35 170
p50 0.20 0.27 0.37 170
p90 0.20 0.27 0.44 239
Fig. 5. Comparison of simulated lung doses of asthmatic patients and healthy individuals
expressed as percent of nominal emitted dose with lung dose values of Mariotti et al.
(2011) measured by scintigraphic methods.
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proﬁle to that in Fig. 3B; a saturated aqueous solution of the insoluble
species was often so low in concentration that the evaporation curve
had an appearance that resembled the evaporation of a pure water
droplet. Instead, a more concentrated solution of the insoluble species
was prepared in ethanol and injected into the trap at elevated RH (as
high as 95%) in a similar way to the earlier measurements. The rapid
loss of ethanol and condensation of water led to the equilibration of an
aqueous solute droplet with a much higher solute mass and larger size
than could be achieved by dissolving straight in water. Then, based on
the known mass of solute derived from the size of the original ethanol
droplet, the approach to an equilibrium size in the evaporation proﬁle
at times close to 10 s could be compared with simulations of the ex-
pected proﬁles for droplets of varying hygroscopic response. For con-
venience, κ-Kohler theory was chosen to represent the simulated form
of the hygroscopic thermodynamic response; this theory is extensively
used in aerosol science to reduce the hygroscopic response to a single
number, the value of κ (Petters and Kreidenweis, 2007). In these cases,
the relationship between radial growth factor (GF) and water activity
(aw) is estimated from the relationship:
= = = +
−
RadialGrowthFactor GF DropletRadius a
DropletRadius Dry
ka
a
( )
( )
1
1
w w
w
3
(2)
Fig. 4A shows the functional forms of Eq. (2) for diﬀerent values of
κ. The simulated change in the time-dependence of the size during
evaporation to changes in κ is shown in Fig. 4B. Although not providing
a comprehensive representation of the thermodynamics, if the mea-
sured evaporation proﬁles close to equilibration in size are compared
and related to the initial composition, then the time-dependent proﬁles
can be used to diﬀerentiation between particles of diﬀering κ values.
Thus, by using this approach it was possible to establish an upper limit
of hygroscopic growth, i.e. an upper limit on κ. For a more extensive
description of this technique, refer to the Supplementary information.
2.3. Description of the computational method
The numerical model used in this work is a stochastic whole airway
deposition model. The inputs of the model are the parameters related to
breathing and drug particles, while the output can be the whole re-
spiratory tract, regional (e.g. upper airways, bronchial airways, acinar
airways), lobar, or airway generation number speciﬁc deposition frac-
tions. The model was initially developed by Koblinger and Hofmann
(1990). In this study the model has been adapted and validated for the
case of medical aerosols. Upper airway deposition of the inhaled aerosol
drugs is computed based on empirical deposition formulas of Cheng
(2003). The asymmetrical geometry of the bronchial and bronchiolar
airways is based on the statistical analysis of morphometrical data
published by Raabe et al. (1976). Airway lengths and diameters, and
branching and gravity angles are selected by Monte Carlo techniques.
The acinar part is constructed based on the information retrieved in the
work of Haefeli-Bleuer and Weibel (1988). Deposition of the inhaled
particles in each conducting airway generation is computed based on
theoretical formulas of gravitational settling, inertial impaction and
thermal diﬀusion valid for straight and bent tubes. The same deposition
mechanisms are accounted for in the region of acinar airways. The
model is able to handle any particle size distribution and track the
particles inhaled uniformly during the inspiratory phase, but also in-
haled as an aerosol bolus. Pasquali et al. (2015) has demonstrated that
the ﬂuidisation event is very short and the drug is released from the
NEXThaler® within 0.1–0.2 s. Tweedie and his co-workers (Tweedie
et al., 2015; Tweedie and Lewis, 2016) performed optical measure-
ments and deduced the starting time, time of the peak intensity and
duration of the aerosol bolus emitted by the NEXThaler® devices with
and without a BAM. The measured values, which were implemented
Table 3
Mass of BDP and FF deposited in the throat (THR), preseparator (PRE), on diﬀerent stages (S1-S7) of the impactor and in the micro-oriﬁce collector (MOC).
Flow Stage Size range (μm) Deposited dose (μg) Standard deviation (μg)
BAM no-BAM BAM no-BAM
BDP FF BDP FF BDP FF BDP FF
p10 THR >17.3 12.340 0.617 12.176 0.658 1.024 0.044 0.881 0.083
p10 PRE 13.9–17.3 27.540 1.515 50.559 3.016 2.834 0.139 1.459 0.073
p10 S1 9.41−13.9 0.251 0.027 0.520 0.043 0.036 0.002 0.004 0.003
p10 S2 5.18−9.41 1.159 0.063 1.813 0.104 0.090 0.003 0.045 0.018
p10 S3 3.26−5.18 3.120 0.167 3.047 0.157 0.226 0.022 0.364 0.005
p10 S4 1.9−3.26 5.480 0.495 4.629 0.337 0.441 0.043 0.212 0.007
p10 S5 1.09−1.9 7.668 0.647 4.303 0.337 0.904 0.070 0.244 0.006
p10 S6 0.65−1.09 7.960 0.481 3.217 0.192 1.136 0.067 0.118 0.009
p10 S7 0.41−0.65 3.841 0.204 1.451 0.095 0.301 0.014 0.282 0.009
p10 MOC <0.41 9.253 0.440 3.735 0.177 0.441 0.016 0.343 0.023
p50 THR >14.4 13.042 0.657 14.404 0.802 0.903 0.082 1.406 0.090
p50 PRE 12.8–14.4 28.365 1.633 46.257 2.738 0.632 0.130 1.875 0.129
p50 S1 8.06−12.8 0.555 0.046 0.891 0.066 0.131 0.012 0.119 0.007
p50 S2 4.46−8.06 1.977 0.110 2.452 0.131 0.181 0.011 0.042 0.004
p50 S3 2.82−4.46 4.411 0.305 3.749 0.224 0.337 0.038 0.297 0.022
p50 S4 1.66−2.82 6.998 0.693 4.790 0.417 0.227 0.041 0.749 0.053
p50 S5 0.94−1.66 8.124 0.665 4.120 0.323 0.124 0.023 0.753 0.059
p50 S6 0.55−0.94 7.154 0.426 2.794 0.176 0.101 0.025 0.298 0.020
p50 S7 0.34−0.55 4.289 0.241 2.041 0.129 0.085 0.008 0.971 0.062
p50 MOC <0.34 10.315 0.486 3.676 0.167 0.081 0.004 0.886 0.044
p90 THR – 13.320 0.760 13.801 0.775 0.270 0.035 1.444 0.167
p90 PRE >9.7 25.120 1.534 43.978 2.593 0.990 0.224 1.370 0.021
p90 S1 6.12−9.7 1.476 0.082 1.828 0.117 0.256 0.016 0.280 0.004
p90 S2 3.42−6.12 3.793 0.246 3.366 0.194 0.135 0.019 0.308 0.017
p90 S3 2.18−3.42 6.027 0.553 4.253 0.353 0.191 0.018 0.459 0.036
p90 S4 1.31−2.18 7.584 0.771 5.117 0.464 0.308 0.013 0.974 0.101
p90 S5 0.72−1.31 7.323 0.538 4.277 0.299 0.381 0.021 0.593 0.036
p90 S6 0.4−0.72 5.299 0.327 2.902 0.176 0.047 0.017 0.788 0.025
p90 S7 0.24−0.4 3.982 0.237 1.995 0.121 0.056 0.031 0.442 0.008
p90 MOC <0.24 9.279 0.390 5.214 0.228 0.899 0.046 1.215 0.075
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into the numerical model, are summarized in Table 2.
Contrary to the most of current particle deposition models, our
model can be applied also in case of asymmetrical breathing cycles and
breathing patterns containing breath-holds. A recent major develop-
ment of the model regarded the implementation of algorithms aiming at
computing the deposition based on the realistic breathing curve. Earlier
versions dealt with constant inspiratory and expiratory ﬂow rates based
on the inhaled/exhaled volume and inhalation and exhalation times.
The deposition model has been earlier validated based on experimental
scintigraphic deposition data (see Farkas et al., 2016). Since in this
work the model was applied to compute the deposition of Foster®
NEXThaler® drug particles, present validation process consisted in
comparing our theoretical deposition results with deposition data of
Foster® NEXThaler® yielded by the scintigraphic experiments of Mariotti
Fig. 6. Size distributions of BDP (left panels) and FF (right panels) drug components originating from NEXThaler® inhalers with BAM and without BAM corresponding to p10 (upper
panels), p50 (middle panels) and p90 (bottom panels) inhalation proﬁles. All values are expressed as a percent of metered dose. The ﬁgure shows the mean values for 3 inhalers and 5
shots/inhaler.
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et al. (2011). The outcome of this comparison can be seen in Fig. 5. As
the ﬁgure demonstrates the modelling results are in good agreement
with the measurements performed for similar input data values. The
diﬀerences between the measured and simulated lung doses are lower
than the uncertainties of the measurements shown by the error bars.
The good agreement between the calculated and experimentally de-
termined deposition values indicates that our model is suitable for the
simulation of Foster® NEXThaler® deposition.
3. Results
The results of the NGI measurements of BDP and FF masses emitted
by NEXThaler® inhalers with and without BAM corresponding to the
inhalation proﬁles in Fig. 1 are presented in Table 3. The measurement
errors corresponding to the measured quantities are demonstrated as
well. The size intervals corresponding to the throat, preseparator, im-
pactor stages and MOC (micro-oriﬁce collector) are also provided. The
cut-oﬀ diameter values of the throat and prseparator were derived from
the works of Roberts et al. (2000), Zhou et al. (2011), Marple et al.
(2003) and Cheng et al. (2015).
It is worth noting that since the ﬂow rates are diﬀerent in the case of
p10, p50 and p90 proﬁles, diﬀerent cut-oﬀ diameters correspond to
stages with the same name. In addition, the cut-oﬀ diameters of the
throat and pre-separator are also ﬂow rate dependent. To facilitate the
interpretation of size distributions at diﬀerent ﬂow rates, and later their
eﬀect on airway deposition distribution, the results in Table 3 were
processed to represent all size proﬁles using the same size bins. These
proﬁles are presented in Fig. 6. As Fig. 6 demonstrates the inhaler
containing a BAM emits signiﬁcantly lower number of large particles
and higher number of small particles. The mass of drug emitted and
deposited in the preseparator by the NEXThaler® was determined to be
32 ± 3% (with BAM) and 54 ± 4% (without BAM). Thus, sig-
niﬁcantly more drug mass was found to reach the cascade impactor
stages associated with therapeutic dose when the BAM was present.
The role of BAM is to delay the release of powder until the ﬂow
velocity is suﬃciently high. This high ﬂow rate leads to high turbulence
intensity in the cyclone chamber. Inhaled air enters this part of the
inhaler and forms a cyclonic ﬂow. Turbulent airﬂow and particle-wall
collisions lead to both powder de-aggregation and release of active
substance detachment from the carriers. These observations are re-
ﬂected in the higher ﬁne particle fractions emitted by the NEXThaler®
with BAM. The exact values of ﬁne particle fractions are presented in
Table 4 together with the shot weights, delivered doses and ﬁne particle
dose values. Based on Table 4 the FPF of BDP varies between 47 and
51% if the BAM is present and between only 24–30% if the BAM is
missing. Similarly, the FPF of FF takes values between 52 and 55% if
the with BAM included and between only 25–34% without BAM. The
signiﬁcantly higher FPF values obtained for the inhaler with BAM in-
dicates a potential for higher lung depositions.
To quantify the expected increase of lung deposition the numerical
model described in the Methods section has been applied. Fig. 7 depicts
the BDP (left panels) and FF (right panels) deposited extrathoracic and
lung doses in case of p10 (upper panels), p50 (middle panels) and p90
(bottom panels) inhalation proﬁles for the inhalers with BAM and
without BAM, expressed as a percent of metered dose. As it can be
observed in the panels of Fig. 7, deposited upper airway and lung doses
do not sum up to 100%. The remaining fraction corresponds to the
exhaled fraction (emitted dose demonstrated in Table 4 minus total
airway dose presented in Fig. 7) and the dose fraction deposited in the
device (metered dose or label claim minus emitted dose).
Since the patient information leaﬂet (PIL) of Foster® NEXThaler®
advices 5 s to 10 s of breath-hold after the inhalation of the drug, the
results in Fig. 7 refer to these two reference breath-hold time (BH)
values. As a general tendency, for every inhalation proﬁle the upper
airway dose decreased and the lung dose increased by the inclusion of
BAM, except the BDP deposition at p10 for the lower breath-hold time.
The upper airway deposition of BDP decreased from about 60% to
about 40%, while the FF deposition in the same region decreased from
about 60% to 35–40% for the inhaler with BAM compared to the in-
haler with no-BAM. Nevertheless, extrathoracic deposition of the drug
emitted by the same inhaler (with BAM or without BAM) remained
relatively unchanged for the three ﬂow proﬁles. Deposition in the ET
region is mostly due to inertial impaction, which increase with both the
increase of particle size and air velocity. In the present case particle
velocities increase from p10 to p50 then towards p90, but particle
diameters (masses) decrease. ET deposition is a result of the two com-
peting tendencies. At the same time, the lung dose of BDP increased
mostly for the p50 (from 19–21% to 30–38%) and p90 (from 25–26% to
39–41%) proﬁles. By the same token, lung deposition of FF increased
from 21–23% to 38–39% at p50 and from 28–30% to 46–48% at p90
proﬁle. All deposition values are expressed as a percent of the metered
dose (label claim).
Based on our experiments, hygroscopic growth of drug particles can
be important. The hygroscopic response of saline (NaCl), lactose (mi-
cronized LH300), BDP and FF were measured using the CK-EDB and are
presented in Fig. 8. While full hygroscopic response curves were mea-
sured for saline and lactose, the hygroscopic response of BDP and FF
were estimated from the shape of the limiting behaviour on ap-
proaching equilibrium and comparison with the simulated evaporation
curves for droplets of varying κ. The low values of κ for these com-
pounds are consistent with highly insoluble compounds (Petters and
Kreidenweis, 2007).
To demonstrate the eﬀect of hygroscopic growth on drug airway
deposition the lung deposition values for p10 proﬁle were recalculated
by considering the hygroscopic changes in particle diameters. To cover
the whole size distributions measured by the impactor for the p10
proﬁle (Fig. 6, upper panels) nine diﬀerent initial diameter values were
considered (0.3 μm, 0.5 μm, 0.9 μm, 1.5 μm, 2.6 μm, 4.3 μm, 7.3 μm,
Table 4
Shot weight, delivered dose (DD), ﬁne particle dose (FPD) and ﬁne particle fraction (FPF) values with standard deviations of BDP and FF drug components emitted by NEXThaler® inhalers
with and without BAM corresponding to p10, p50 and p90 inhalation proﬁles.
BAM no-BAM
p10 p50 p90 p10 p50 p90
BDP FF BDP FF BDP FF BDP FF BDP FF BDP FF
Shot weight (mg) 8.6
(0.3)
8.6
(0.3)
8.8
(0.4)
8.8
(0.4)
8.6
(0.4)
8.6
(0.4)
9.0
(0.4)
9.0
(0.4)
8.8
(0.2)
8.8
(0.2)
8.8
(0.2)
8.8
(0.2)
Delivered Dose (μg) 78.6
(5.7)
4.7
(0.3)
85.2
(2.3)
5.3
(0.3)
83.2
(3.4)
5.4
(0.4)
85.5
(0.1)
5.1
(0.1)
85.2
(2.6)
5.2
(0.2)
86.7
(2.1)
5.3
(1.8)
Fine Particle Dose (μg) 37.2
(3.4)
2.4
(0.2)
41.9
(0.9)
2.8
(0.1)
42.4
(1.9)
3.0
(0.2)
20.2
(0.5)
1.3
(0.0)
21.8
(3.4)
1.5
(0.2)
26.2
(2.2)
1.8
(0.2)
Fine Particle Fraction (%) 47.3
(1.8)
52.1
(1.9)
49.1
(0.3)
54.2
(1.3)
50.9
(0.2)
55.3
(1.6)
23.6
(0.6)
25.1
(0.6)
25.6
(3.8)
28.4
(4.2)
30.2
(1.8)
33.5
(2.1)
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11.7 μm, 15 μm). Fig. 9 shows the post-inhalation time dependence of
the diameters of FF, BDP and lactose particles with given diameters at
the moment of inhalation. Note that particle size at inhalation depends
on the RH the particle is in equilibrium with prior to inhalation. For the
sake of simplicity, in the following sample calculations it was con-
sidered that at inhalation RH = 50%, similar to the value characteristic
of the laboratory environment during the size distribution
measurements. For other values of RH at inhalation the measured size
distribution can be converted by ﬁrst determining the dry (RH = 0%)
size distribution, then computing the sizes for the corresponding non-
zero RH value. Table 5 reports the dry diameters of the particle sizes
considered at RH = 50%.
Taking into account hygroscopic growth of particles shown in Fig. 9,
lung deposition of Foster® NEXThaler® at p10 proﬁle changes compared
Fig. 7. Comparison of BDP (left panels) and FF (right panels) deposited extrathoracic and lung doses in case of p10 (upper panels), p50 (middle panels) and p90 (bottom panels)
inhalation proﬁles assuming 5 s and 10 s breath-hold times (BH) for the inhalers with BAM and without BAM, expressed as a percent of metered dose.
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to that demonstrated in Fig. 7 (upper panels). The new values are de-
picted in Fig. 10. The ﬁgure demonstrates that the existence of BAM
leads to the increase of lung dose even for the weakest inhalation proﬁle
(p10), which was not obvious without considering the hygroscopic
growth of drug particles. Actually, the diﬀerences in Fig. 10 are the
result of three major factors. Indeed, size distribution diﬀerences be-
tween BAM and no-BAM are evident even for the lowest studied in-
halation strength causing lower upper airway and higher lung deposi-
tion when BAM is present. However, this eﬀect is counterbalanced by
the fact that in no-BAM case particles are released sooner and have
more chances to penetrate deeper and more time to deposit by grav-
itational settling. Actually, these two competing mechanisms are at play
also for the higher ﬂow rates, but there the release of particles happens
earlier (see Table 2) even with BAM and the inhaled volume is also
higher, thus small particles have more chances to reach the lungs. What
Fig. 10 intends to highlight is the eﬀect of the third factor, that is,
hygroscopic growth. By this eﬀect particles which were small enough to
enter the lungs become larger and deposit more eﬃciently by impaction
(which is not time dependent).
4. Discussion
Regardless to the inhalation proﬁle used, an increased fraction of
Fig. 8. (A) Summary of the hygroscopic behaviour of soluble and highly insoluble pharmaceutics measured. The value of κ for FF is 0.01 (+/− 0.005) and for BDP is 0.02 (+/− 0.005)
while the radial growth factors for NaCl and Lactose were measured from the mass ﬂux. (B) Based on the hygroscopic growth measurements, simulations of the growth kinetics of the
radius of an FF droplet with initial diameter of 1.5 μm. Calculations are shown at three diﬀerent starting relative humidities with the droplet at equilibrium prior to inhalation (0 s
corresponds to the moment of inhalation). RH in the airways is 99.5%.
Fig. 9. Hygroscopic growth of FF (panel A), BDP (panel B) and lactose (Panel C) particle diameters after the inhalation assuming ambient RH value of 50% and lung RH value of 99.5%.
Table 5
Dry diameters of BDP and FF particles corresponding to their RH = 50% diameters.
Diameter at RH = 50% (μm) Diameter at RH = 0% (μm)
BDP FF
0.3 0.30 0.30
0.5 0.50 0.50
0.9 0.89 0.90
1.5 1.49 1.50
2.6 2.58 2.59
4.3 4.17 4.19
7.3 7.25 7.28
11.7 11.62 11.66
15.6 15.50 15.55
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both BDP and FF is observed in the pre-separator when the BAM is pre-
triggered by the analyst. This corresponds to a reduced NGI stage de-
position and consequently a lower ﬁne particle dose. With the BAM
present, the ﬁne particle dose is greatly improved, less material is found
in the pre-separator, more in the lower stages with a noticeable increase
in MOC. This eﬀect is likely to be due to the increased entrainment air
velocity caused by the delayed entrainment and dispersion of the for-
mulation when the BAM is present. Indeed, earlier works have de-
monstrated that the NEXThaler® device starts emitting the drug when
the ﬂow rate of the patient reaches a value of about 35 L/min (Corradi
et al., 2014; Pasquali et al., 2015; Mason et al., 2015). The higher ﬂow-
rate means higher air velocity, thus higher turbulence intensity inside
the cyclone chamber. In addition, particle-particle and particle-device
wall collisions are more powerful. As a consequence, the detachment of
drug particles from the carriers is more eﬃcient and more small par-
ticles are emitted from the device. Present numerical computations
demonstrated that the higher FPF translates into lower upper airway
doses and higher deposited doses in the lungs. In this way, the prob-
ability of the unwanted side eﬀects decreases and the likelihood that
the drug reaches the receptors increases. In this work the clinical eﬀect
was not investigated, however, increased lung deposition most prob-
ably contributes to a more eﬃcient therapy. The only exception from
the tendencies described above was the case of p10 proﬁle, where the
lung doses corresponding to the BAM and no-BAM cases are about the
same (Fig. 7, upper right panel). The explanation for this apparent
exception is the presence of two competing eﬀects. The ﬁrst eﬀect is
related to the inhaled particle size distribution and the second to the
inhalation time of the particles. With regards to the p10 inhalation
proﬁle, particles penetrate deeper into the lungs when no BAM is pre-
sent. This is because the aerosol bolus is emitted earlier from the in-
haler; i.e. prior to the pressure drop required to trigger the BAM. If the
particles are small (< 3 μm) deposition within the respiratory tract is
dominated by sedimentation and diﬀusion within the deep lung.
However, deposition by sedimentation and diﬀusion is less dominant
for larger particles which mainly deposit by impaction in the or-
opharynx and bronchi, i.e. prior to reaching the lungs. It therefore
follows, that total lung deposition is a function of the inhaled particle
size distribution and the point at which the particles are inhaled. For
the higher capacity inhalation proﬁles p50 and p90 sedimentation and
diﬀusion are predominant and lung deposition is increased when the
BAM is present. For the lower capacity inhalation proﬁle, p10, a small
amount of air is slowly inhaled (about 0.6 L). Thus for the p10 case,
particles, which are emitted in a later phase of the inhalation (from
0.44 s in the BAM case) will not enter the deeper regions of the lung and
sedimentation and diﬀusion mechanisms will be less signiﬁcant. As a
result, the observed advantages of the BAM with inhalation proﬁles p50
and p90 are less evident for the p10 inhalation proﬁle.
Finally, all the results in Fig. 7 may be aﬀected by particle hygro-
scopicity. If hygroscopic growth is relevant, then particle sizes shift
towards higher diameter values and the second eﬀect mentioned above
is not so powerful. As a result, the BAM case yields higher lung de-
position even for p10 inhalation ﬂow proﬁle (Fig. 10). Indeed, present
hygroscopicity measurements yielded κ values of 0.010 ± 0.005 for FF
and 0.020 ± 0.005 for BDP of a 1.5 μm particle (comparable to the
measured values of FF and BDP MMADs), which at RH = 99.5%
translates into radial growth factors of 1.4 and 1.7, respectively. Time
scales of inhalation and exhalation plus a 5–10 s breath-hold brings us
into the region where hygroscopic growth factors are relevant. Indeed,
the results depicted in Fig. 10 clearly demonstrate that considering
realistic hygroscopic growth leads to higher lung depositions of BDP
and FF for the inhalers with BAM than for the inhalers without BAM for
both 5 s and 10 s breath-hold times even for the weakest inhalation
proﬁle (p10). This result emphasizes the importance of measuring the
hygroscopic behaviour of all the marketed drugs and drug components
but also the necessity of the inclusion of the hygroscopic eﬀect into the
numerical deposition models in the future.
5. Conclusions
As inhaler devices become more sophisticated and development of
connected smart inhaler devices become publicised (Chan et al., 2015),
the NEXThaler® remains a relatively new device with several in-
novative, yet non-electronic, features. In particular, a breath actuated
mechanism (BAM) has been incorporated into the design. To the best of
our knowledge the present work is the ﬁrst systematic study regarding
the eﬀect of this mechanism on the airway deposition of Foster® NEX-
Thaler®. Based on the results of this study the BAM leads to; a reduction
in the large particles emitted; lower upper airway deposited doses; an
increase in the available therapeutic ﬁne particle fraction (FPF); re-
sulting in a signiﬁcantly higher lung dose. The observations from our
study suggest inclusion of the BAM provides an improved clinical out-
come. This work has also demonstrated that hygroscopicity may play an
important role in lung deposition. Knowledge of particle growth dy-
namics, particle residence times within diﬀerent regions of the airways
and deposition distributions may lead to a more intelligent drug de-
velopment in the future to decrease upper airway drug deposition and
increase it in the targeted regions.
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